Errata and Corrigenda

The publishers and the authors would like to make the following corrections:

Young, A.A., Crocker, L.B.,Wolfe-Lopez, D. and Cooper, G.J.S., Daily amylin replacement reverses hepatic glycogen depletion in insulin-treated streptozotocin diabetic rats (1991) FEBS Letters 287, 203–205

Due to a numerical error in the derivation of hepatic glycogen contents, published values should be multiplied by a factor of 6.19. The conclusions of the paper are not altered; the P value at an amylin dose of 30 μg/day changes from < 0.02 to < 0.03.

Arcone, R., Fontaine, V., Coto, I., Content, J., Brakenhoff, J.P.J. and Ciliberto, G., Internal deletions of amino acids 29–42 of human interleukin-6 (IL-6) differentially affect bioactivity and folding (1991) FEBS Letters 288, 197–200

The name and address of Author Brakenhoff was omitted. The correct list of authors and their affiliations should have been as follows:

Rosaria Arcone[1], Veronique Fontaine[2], Iolanda Coto[1], Just P.J. Brakenhoff[3], Jean Content[2] and Gennaro Ciliberto[4]

[1]*CEINGE, Centro di Ingegneria Genetica, Via S. Pansini 5, 80131, Napoli, Italy,* [2]*Institut Pasteur du Brabant, Department of Virology, 1180 Bruxelles, Belgium,* [3]*Central Laboratory of the Netherlands Red Cross Blood Transfusion Service, Amsterdam, The Netherlands* and [4]*I.R.B.M., Via Pontina km 30,600, 00040 Pomezia, Rome, Italy*

The list of points made in section 3, Results and Discussion, p. 199, should have been as follows:

- Wild-type IL-6 is recognized at high efficiency by mAb 8 but not by mAb 7.
- The active mutant Δ39–42 behaves similarly, but here there is a moderate reaction with mAb 7, probably a sign of partial denaturation of the protein. This result is in line with the slight decrease of activity that this mutant protein shows.
- Mutants Δ31–34 and Δ35–38 behave inversely: their recognition by mAb 8 is considerably decreased and at the same time the mutant proteins are precipitated efficiently by mAb 7 (ratio mAb 7/mAb 8=0.8). This is clear evidence that these proteins are denaturated, and explains lack of activity.
- The most interesting mutant is Δ29–30. Its immunoreactivity is intermediate between that of mutant Δ39–42 and that of mutants Δ31–34 and Δ35–38 (ratio mAb 7/mAb 8=0.56). This leads to the conclusion that the deletion of amino acids 29–30 is accompanied by a minor degree of structural alteration but its bioactivity is 10- to 20-fold lower than that of Δ35–38.

Table II, p. 200 was also incorrect and should have been as follows:

Table II
Conformational analysis of the deletion mutants

Proteins	Immunoprecipitation with				or without
	polyclonal Ab	mAb 7	mAb 8	mAb 7/mAb 8	anti IL-6 Ab
wt IL-6	+	–	++	0.08	–
Δ29–30	+	+	++	0.56	–
Δ31–34	+	++	++	0.77	–
Δ35–38	+	+	+	0.81	–
Δ39–42	+	+/-	++	0.26	–